ClinicalTrials.gg
RecruitingNCT06968962ORIENTATIONUpdated Jul 29, 2025

Comparison of Sequential to Initial Combination Therapy in PAH

An interventional study of Tadalafil and Ambrisentan in Pulmonary Arterial Hypertension (PAH), sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
376
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies testing ambrisentan in Pulmonary Arterial Hypertension — 4 open to participants now, 4 under way, 1 of them phase 3. ambrisentan · Pulmonary Arterial Hypertension.

Planned enrollment
5th of 20
376 · median 80
Started
2025
with 1 other
No phase
3 of 20
3 open now
Registered
18th of 20
by date
Lead sponsor
1 of 20
Second Affiliated Hospital, School of Medicine, Zhejiang University

Among the 20 studies testing ambrisentan in Pulmonary Arterial Hypertension, this one is the 5th largest by planned enrollment, is one of 2 that started in 2025, is one of 3 with no phase, and was the 18th registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

4 of the 20 studies testing ambrisentan in Pulmonary Arterial Hypertension are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ambrisentan

ambrisentan: first FDA approval 2007 (LETAIRIS), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing ambrisentan in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

This is a multicenter, randomized, controlled, double-blind, and non-inferiority clinical trial to compare the efficacy of sequential to initial combination therapy in patients with pulmonary arterial hypertension (PAH). Ambrisentan and Tadalafil will be used in the study. Our research hypothesis is that the efficacy of sequential combination therapy in PAH patients is not inferior to the initial combination therapy as the primary efficacy endpoint is the change in 6MWD at month 12 from baseline.

Read the detailed description

This is a multicenter, randomized, controlled, double-blind, and non-inferiority clinical trial to compare the efficacy of sequential to initial combination therapy in symptomatic patients with PAH (WHO functional class I-III) and assessed as low-risk or moderate-risk based on 2022 ESC/ERS risk stratification. Subjects must not have previously received chronic PAH therapy (i.e., prostanoids, ERAs, or PDE-5 inhibitors) within 4 weeks prior to Screening.

Treatment Escalation

1. The investigators will conduct a risk stratification assessment based on COMPERA 2.0 every 4 months, i.e. at month 4, 8, and 12.

2. If the patient meets the low-risk criteria, their current treatment regimen will be maintained, and both the patient and the investigator will be unaware of the specific regimen.

3. If the patient does not meet the low-risk criteria:

  1. No clinical failure events have occurred: The first step is to escalate to blinded dual therapy.

    1. The investigator initiates a request for blinded dual therapy, and the pharmacist informs the investigator that the treatment plan has been upgraded as requested.
    2. If the patient is currently on mono therapy, the pharmacist will escalate the regimen to dual therapy.
    3. If the patient is currently in the initial combination therapy group or has already escalated to blinded dual therapy, the pharmacist will maintain the current dual therapy regimen.
  2. If any clinical failure event occurs at any time, as determined by the Clinical Event Evaluation Committee:

    1. Escalate to blinded dual therapy as described above
    2. Or add prostacyclin analogue
    3. Or add IP receptor agonist
    4. Or transition of Tadalafil to Riociguat
    5. Or add Sotatercept

Primary efficacy endpoint is exercise capacity, as the change in 6MWD at month 12 from baseline. Secondary efficacy endpoints will include time to clinical failure events during the 12-month treatment period, and others detailed in outcome measures.

Study duration will be approximately 4 years. A non-inferiority test will be conducted based on the mean difference and 95% CI of the change in 6MWD between groups after 12 months of treatment following randomization. An unblinded, external, independent DSMB will monitor participants' data and safety throughout the course of the study.

03

Conditions studied

  • Pulmonary Arterial Hypertension (PAH)

Keywords

  • Sequential combination therapy
  • Initial combination therapy
  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 to 80 years and weight ≥ 40 kg.
  2. WHO functional classification I-III.
  3. Diagnosed with PAH caused or related to the following:

1) Idiopathic PAH 2) Hereditary PAH 3) Associated PAH:

  1. Connective tissue diseases (e.g., scleroderma, systemic lupus erythematosus, mixed connective tissue disease, etc.)
  2. Drug or toxin exposure
  3. Corrected congenital heart diseases for more than 1 year (e.g., atrial septal defect, ventricular septal defect, and patent ductus arteriosus) 4. Risk stratification assessed as low-risk or intermediate-risk according to the 2022 ESC/ERS guidelines.

    5. Right heart catheterization meets the following criteria (end-expiratory data, original waveform must be retained for quality control):

    1) Mean pulmonary artery pressure ≥ 25 mmHg 2) Pulmonary vascular resistance ≥ 3 Wood units 3) Pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg 4) Cardiac output measurement requirements: thermal dilution or direct Fick method; indirect Fick method does not meet study criteria.

    6. Pulmonary function tests meet the following criteria:

    1) Total lung capacity (TLC) ≥ 60% of the predicted normal value; 2) (FEV1) ≥ 55% of the predicted normal value; 3) DLCO_SB ≥ 40% of the predicted normal value. 7. Baseline 6MWD more than 100 meters repeated twice at screening (measured at least 4 hours apart, but no longer than 1 week), and both values are within 15% of each other (calculated from the highest value) 8. In a resting state, without supplemental oxygen, arterial oxygen saturation (SaO2) ≥ 88%.

    9. No participation in cardiopulmonary rehabilitation training programs within 12 weeks prior to the screening visit.

    10. Females of must agree to use until the end of the study.

    11. No participation in clinical studies involving other drugs or devices throughout the study duration.

    12. Ability to understand the form and sign it.

Exclusion criteria

Exclusion Criteria:

1. Other types of pulmonary arterial hypertension (PAH)

  1. Other types of PAH, such as -related PAH, schistosomiasis-related PAH, etc.
  2. Pulmonary arterial hypertension associated with portal hypertension
  3. Pulmonary vein occlusive disease or pulmonary capillary hemangiomatosis 2. Group 4 PH, e.g. Chronic thromboembolic pulmonary hypertension 3. Group 2 PH, i.e., PH associated with left heart disease 4. Group 3 PH, i.e., PH associated with lung disease or hypoxia 5. Group 5 PH, i.e., PH with unclear mechanisms or multi-mechanism 6. PAH Therapy

1) Subjects who have received PAH therapy (such as PDE5 inhibitors, ERAs, or chronic prostacyclin therapy) within 4 weeks prior to the screening visit.

2) Subjects who have ever received ERA therapy (e.g., macitentan) or PDE5 inhibitor therapy (e.g., sildenafil) and discontinued due to tolerance issues unrelated to liver dysfunction.

3) Subjects known to have an allergy to the product, its metabolites, or .

7. Other Therapies

  1. Subjects who have received intravenous inotropes (e.g., dobutamine) within 2 weeks prior to the screening visit.
  2. Subjects receiving protease inhibitors, systemic ketoconazole, or systemic itraconazole therapy.
  3. Subjects receiving strong inducers (e.g., rifampicin).
  4. Subjects who have received unstable doses of calcium channel blockers or HMG-CoA reductase inhibitors (statins) within 4 weeks prior to the screening visit (eligible subjects must not have changed doses within 4 weeks prior to the screening visit).
  5. Subjects with a history of angina or who have received long-acting or short-acting nitrate treatment within the 12 weeks prior to the visit.

8. Laboratory Tests at Screening

1) Serum or AST laboratory values > 2 times the at screening.

2) Serum laboratory values > 1.5 times the upper limit of normal at screening.

3) Severe renal impairment (estimated \< 45 mL/min/1.73m3) at screening.

9. Medical History/Current Medical Conditions

  1. Severe liver dysfunction ( Class C, with or without cirrhosis) at screening.
  2. Significant anemia in the opinion of the investigator.
  3. History of bleeding disorders or significant active peptic ulcers.
  4. Uncontrolled hypertension (≥ 180/110 mmHg) at screening.
  5. Severe hypotension (\< 90/50 mmHg) at screening.
  6. Myocardial infarction within 3 months prior to screening.
  7. aortic or mitral valve disease, constrictive pericarditis, restrictive or congestive cardiomyopathy, life-threatening arrhythmias, significant left ventricular dysfunction, left ventricular outflow tract obstruction, symptomatic coronary artery disease, autonomic hypotension, or circulatory failure.
  8. History of non-arteritic anterior ischemic optic neuropathy.
  9. Hereditary degenerative retinal disease (e.g., retinitis pigmentosa).
  10. Significant fluid retention in the opinion of the investigator.
  11. Subjects with cardiovascular, liver, kidney, hematologic, gastrointestinal, immune, endocrine, metabolic, or central nervous system diseases that the investigator believes may adversely affect the subject's safety and/or the efficacy of the investigational product or significantly impact the subject's lifespan.
  12. History of malignant tumors within the past 5 years, except for those with local, non- basal cell carcinoma, cervical carcinoma in situ, or prostate cancer who are not anticipated to receive radiotherapy, chemotherapy, and/or surgical interventions or initiate hormonal therapy during the study period.
  13. Pregnant or breastfeeding female subjects.
  14. Subjects with demonstrated poor compliance.
  15. History of alcohol abuse or illicit drug use within 1 year.
  16. Participation in clinical studies involving another investigational drug or device within 4 weeks prior to the screening visit.

Subjects who fail inclusion/exclusion criteria may be re-screened once.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
376 participants (estimated)

Study arms

  • Active comparator
    Initial combination therapy

    Patients will receive dual combination therapy with Ambrisentan and Tadalafil immediately after randomization.

    Drug: Tadalafil · Drug: Ambrisentan

  • Experimental
    Sequential combination therapy (B1 group)

    Patients will receive Ambrisentan and Tadalafil mimic first, with sequential addition of Tadalafil if low risk status was not achived at month 4, or 8, or 12.

    Drug: Ambrisentan · Drug: Tadalafil mimic

  • Experimental
    Sequential combination therapy (B2 group)

    Patients will receive Tadalafil and Ambrisentan mimic first, with sequential addition of Ambrisentan if low risk status was not achived at month 4, or 8, or 12.

    Drug: Tadalafil · Drug: Ambrisentan mimic

Interventions

  • Target dose 40 mg OD

  • Target dose 10 mg OD

  • DrugAmbrisentan mimic

    Ambrisentan mimic will switch to Ambrisentan if low risk status was not achived at month 4, or 8, or 12.

  • DrugTadalafil mimic

    Tadalafil mimic will switch to Tadalafil if low risk status was not achived at month 4, or 8, or 12.

06

What researchers measure

Primary outcomes

  1. The change of 6MWD at month 12 from baseline

    The 6MWD was the distance walked in 6 minutes as a measure of functional capacity. This was assessed using the 6-minute walk test (6MWT).

    Time frame: Baseline and Month 12

Secondary outcomes

  1. Time to clinical failure events during the 12-month treatment period.

    Definition of Clinical Failure Events: 1. Death (all-cause) 2. Hospitalization due to worsening PAH (adjudicated) 1. Any hospitalization for worsening 2. PAH Lung or heart/lung transplantation 3. Atrial septostomy 4. Initiation of parenteral prostanoid therapy 5. Need to initiate rescue therapy <!-- --> 1. Switch Tadalafil to Macitentan 2. Add Selexipag 3. Add Sotatercept 3. Disease progression (adjudicated) 1. Decrease in 6MWD of more than 15% from baseline 2. Concurrent presence of WHO functional class III or IV symptoms (continuously observed in follow-up after baseline with at least 14 days apart) 4. Unsatisfactory long-term clinical response (Adjudicated, all criteria must be met) 1. Receiving at least one dose of randomized treatment and being in the study for at least 6 months 2. A decrease in 6MWD from baseline in two assessments separated by at least 14 days 3. WHO functional class III symptoms assessed at two visits separated by \> 6 months

    Time frame: During the 12-month treatment period

  2. Low-risk status achievement rates.

    Risk stratification will be assess according to COMPERA 2.0, which includes WHO functional class, 6MWD, and BNP or NT-proBNP.

    Time frame: Month 4, 8 and 12

  3. The change of NT-proBNP at month 12 from baseline

    NT-proBNP is a circulating biomarker that reflects cardiac afterload, this will be measured by central lab.

    Time frame: Baseline and Month 12

  4. The change of WHO functional class at month 12 from baseline

    WHO functional classification for PAH ranges from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest).

    Time frame: Baseline and Month 12

  5. The change of pulmonary vascular resistance at month 12 from baseline

    Pulmonary vascular resistance is a hemodynamic variable of pulmonary circulation and was measured by right heart catheterization.

    Time frame: Baseline and Month 12

  6. Percentage of subjects receiving mono, dual or triple therapy

    Time frame: Month 4, 8, and 12

  7. Percentage of subjects with satisfactory clinical response

    1. An increase of 10% in 6MWD compared to baseline. 2. Improvement or maintenance of WHO class I or II symptoms. 3. No clinical failure events occurring during the study.

    Time frame: Month 8, and 12

  8. The change of EmPHasis-10 score from baseline

    The EmPHasis-10 questionnaire is used during clinical assessments to estimate how pulmonary hypertension affects patients' life (range: 0=no impact to 5=severe impact). A higher score indicated more severe impact.

    Time frame: Baseline, Month 4, 8, and 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2028, 36 months after the start.

Of 60 non-industry interventional studies with no phase under Pulmonary Arterial Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 63. This study's planned 36 months is below that.

Counting every sponsor, half of 65 studies reached it within 42 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2025
First posted
May 13, 2025
StartActual
May 14, 2025
Primary completionEst.
May 2028
CompletionEst.
Dec 2028
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06968962
Collaborators
Huzhou Central Hospital, Ningbo Medical Center Lihuili Hospital, First Affiliated Hospital of Ningbo University, Ningbo No.2 Hospital, Affiliated Hospital of Jiaxing University, The Second Affiliated Hospital of Jiaxing University, First Affiliated Hospital of Wenzhou Medical University, Shanghai Pulmonary Hospital, Shanghai, China, Taizhou Hospital, Guangdong Provincial People's Hospital
Responsible party
JianAn Wang (Professor, Second Affiliated Hospital, School of Medicine, Zhejiang University) — Principal investigator
First posted
May 13, 2025
Start date
May 14, 2025
Primary completion
May 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jul 29, 2025

Study contacts

Zongye Cai, MD, PhD
Contact
z.cai@zju.edu.cn
+8618258236820
Zexin Chen
Contact
chenzexin@zju.edu.cn
+86 15867136069

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tadalafil · Ambrisentan

Start the discussion